Detail akcie Cabaletta Bio Rg online

Business Summary: Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cabaletta Bio Inc revenues was not reported. Net loss increased 51% to $125.9M. Higher net loss reflects Interest Income decrease of 42% to $4.7M (income), Stock-based Compensation in R&D increase of 27% to $9.3M (expense), Stock-based Compensation in SGA increase of 10% to $7.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.71 to -$1.88.